Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again

Epratuzumab (anti-CD22) is a humanized monoclonal antibody that recognizes a pan-B-cell marker. It potentially downregulates B cell activity through negative signaling, as well as depleting B cells moderately. The uncontrolled series discussed by Dörner and colleagues in this issue of Arthritis Rese...

Descripción completa

Detalles Bibliográficos
Autor principal: Eisenberg, Robert
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526641/
https://www.ncbi.nlm.nih.gov/pubmed/16732895
http://dx.doi.org/10.1186/ar1967
Descripción
Sumario:Epratuzumab (anti-CD22) is a humanized monoclonal antibody that recognizes a pan-B-cell marker. It potentially downregulates B cell activity through negative signaling, as well as depleting B cells moderately. The uncontrolled series discussed by Dörner and colleagues in this issue of Arthritis Research & Therapy suggests that epratuzumab may be safe and efficacious for systemic lupus erythematosus. A randomized controlled trial is currently active to test this possibility.

Ejemplares similares